Kathleen Danenberg Joins Caris Life Sciences’ Executive Team as Senior Vice President, Professional Affairs Newly Added Position Will Develop and Expand Molecular Profiling Clinical Trial Strategy
IRVING, Texas – October 19, 2011 – Caris Life Sciences, Inc.™, a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic, prognostic and theranostic services, announced today that Kathleen Danenberg has joined the company in the newly-created position of Senior Vice President, Professional Affairs. In this capacity, Ms. Danenberg’s extensive expertise in the personalized medicine landscape will help to shape and advance Caris Life Sciences’ clinical trial strategy, advance and expand the company’s molecular profiling services, and help drive expansion of Caris’ biopharma services.
“I couldn’t be more pleased to join such a forward-thinking organization as Caris,” said Kathleen Danenberg, newly-appointed Senior Vice President, Professional Affairs for Caris Life Sciences. “I have believed for many years that molecularly guided therapy selection is the future of oncology and through work with Caris Life Sciences, I believe I will be able to further the adoption of this cutting-edge approach. I look forward to the important work we will do together.”
After more than 20 years as a laboratory specialist at the University of Southern California, Ms. Danenberg founded clinical genetic testing company, Response Genetics, in 1999 and most recently served as Director and Executive Scientific/Technology Officer. Her distinguished tenure at Response Genetics also includes serving as President, CEO and Chief Scientific Officer, where she established a revenue run rate of about $30 million and completed testing of thousands of patients for GlaxoSmithKline in clinical trials of MAGE A3- and BRAF-targeted therapies. Her impressive credentials include developing and distributing RT-PCR testing for thymidylate synthase as a predictor of 5-Fluorouracil sensitivity in colon cancer. She is the author of more than 170 peer-reviewed publications and was also the recipient of the 2010 “Simply the Best” award from the Addario Cancer Foundation.
“The importance and utilization of personalized medicine tools continues to grow, and Caris Life Sciences continues to be at the forefront of this technological revolution,” said Tom Spalding, Senior Vice President, Group Head Oncology and Chief Marketing Officer at Caris Life Sciences. “Kathleen brings deep experience in the field and excellent relationships to our efforts, and will help to further advance our cutting-edge technology platforms with her strategic insight. We are delighted to have her on the Caris leadership team.”
Caris Target Now is an evidence-based molecular profiling service that matches molecular data generated from the individual patient’s tumor with biomarker/drug associations from nearly 100,000 published clinical studies that are reviewed and graded by Caris’ evidence team of MDs and PhDs. This service provides a simple-to-read report indicating which available chemo, biologic and hormone therapies are more likely to be effective and those that are likely to be ineffective, based on currently available scientific data.